<DOC>
	<DOC>NCT01704534</DOC>
	<brief_summary>The purpose of this study is to determine whether ustekinumab is effective in the treatment of moderate to severe hidradenitis suppurativa.</brief_summary>
	<brief_title>A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa</brief_title>
	<detailed_description>An open label prospective study is performed to investigate the effectiveness and safety of ustekinumab in hidradenitis suppurativa. Twenty patients will be included. They will receive ustekinumab 45 or 90 mg on weeks 0-4-16-28. Patients will be followed up untill week 40.</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>18 years or older Hidradenitis suppurativa Hurley stage II or III No response to conventional local and oral antibiotics, or immunnesuppressive medication, or TNFalpha inhibitors or surgery The patient has to be able to complete a dutch questionnaire Informed consent must be obtained Not able to complete a Dutch questionnaire Pregnancy or breast feeding Active hepatitis B or C infection, HIV or tuberculosis Treatment with biologics or other immunosuppressive medicine in the previous 3 months Malignancies in the last 10 years with the exception of basal cell carcinoma Demyelinating disorders Heart failure Known allergy to ustekinumab or to its preservatives Live vaccins in the next 3 months Sever liver or renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hidradenitis suppurativa</keyword>
	<keyword>Acne ectopica</keyword>
	<keyword>Inverse acne</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Stelara</keyword>
</DOC>